During the last session, Anavex Life Sciences Corporation (NASDAQ:AVXL)’s traded shares were 1.52 million, with the beta value of the company hitting 0.66. At the end of the trading day, the stock’s price was $9.02, reflecting an intraday gain of 6.43% or $0.54. The 52-week high for the AVXL share is $10.45, that puts it down -15.85 from that peak though still a striking 63.97% gain since the share price plummeted to a 52-week low of $3.25. The company’s market capitalization is $764.85M, and the average intraday trading volume over the past 10 days was 1.69 million shares, and the average trade volume was 958.08K shares over the past three months.
Anavex Life Sciences Corporation (AVXL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AVXL has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.17.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Anavex Life Sciences Corporation (NASDAQ:AVXL) trade information
Anavex Life Sciences Corporation (AVXL) registered a 6.43% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 6.43% in intraday trading to $9.02, hitting a weekly high. The stock’s 5-day price performance is 12.33%, and it has moved by 67.35% in 30 days. Based on these gigs, the overall price performance for the year is 34.23%. The short interest in Anavex Life Sciences Corporation (NASDAQ:AVXL) is 18.31 million shares and it means that shorts have 24.67 day(s) to cover.
The consensus price target of analysts on Wall Street is $11, which implies an increase of 18.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $11 and $11 respectively. As a result, AVXL is trading at a discount of -21.95% off the target high and -21.95% off the low.
Anavex Life Sciences Corporation (AVXL) estimates and forecasts
Statistics show that Anavex Life Sciences Corporation has underperformed its competitors in share price, compared to the industry in which it operates. Anavex Life Sciences Corporation (AVXL) shares have gone up 116.31% during the last six months, with a year-to-date growth rate less than the industry average at 8.33% against 18.00. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -41.67% this quarter and then drop -72.73% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -9.03%. While earnings are projected to return 9.32% in 2024.
AVXL Dividends
Anavex Life Sciences Corporation is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Anavex Life Sciences Corporation (NASDAQ:AVXL)’s Major holders
Anavex Life Sciences Corporation insiders own 3.05% of total outstanding shares while institutional holders control 32.06%, with the float percentage being 33.07%. BLACKROCK INC. is the largest shareholder of the company, while 189.0 institutions own stock in it. As of 2024-06-30, the company held over 6.39 million shares (or 7.7506% of all shares), a total value of $26.97 million in shares.
The next largest institutional holding, with 4.55 million shares, is of VANGUARD GROUP INC’s that is approximately 5.5154% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $19.19 million.
